BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28576842)

  • 1. Toward Molecularly Driven Precision Medicine in Lung Adenocarcinoma.
    Liu D; Vokes NI; Van Allen EM
    Cancer Discov; 2017 Jun; 7(6):555-557. PubMed ID: 28576842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.
    Jordan EJ; Kim HR; Arcila ME; Barron D; Chakravarty D; Gao J; Chang MT; Ni A; Kundra R; Jonsson P; Jayakumaran G; Gao SP; Johnsen HC; Hanrahan AJ; Zehir A; Rekhtman N; Ginsberg MS; Li BT; Yu HA; Paik PK; Drilon A; Hellmann MD; Reales DN; Benayed R; Rusch VW; Kris MG; Chaft JE; Baselga J; Taylor BS; Schultz N; Rudin CM; Hyman DM; Berger MF; Solit DB; Ladanyi M; Riely GJ
    Cancer Discov; 2017 Jun; 7(6):596-609. PubMed ID: 28336552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomics driven-oncology: challenges and perspectives.
    Normanno N; Cree IA
    BMC Cancer; 2015 Mar; 15():141. PubMed ID: 25884512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
    Wiesweg M; Eberhardt WEE; Reis H; Ting S; Savvidou N; Skiba C; Herold T; Christoph DC; Meiler J; Worm K; Kasper S; Theegarten D; Hense J; Hager T; Darwiche K; Oezkan F; Aigner C; Welter S; Kühl H; Stuschke M; Schmid KW; Schuler M
    J Thorac Oncol; 2017 Jan; 12(1):54-64. PubMed ID: 27575422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.
    Xia S; Huang CC; Le M; Dittmar R; Du M; Yuan T; Guo Y; Wang Y; Wang X; Tsai S; Suster S; Mackinnon AC; Wang L
    Lung Cancer; 2015 Oct; 90(1):78-84. PubMed ID: 26233568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
    Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
    J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers.
    Robles AI; Arai E; Mathé EA; Okayama H; Schetter AJ; Brown D; Petersen D; Bowman ED; Noro R; Welsh JA; Edelman DC; Stevenson HS; Wang Y; Tsuchiya N; Kohno T; Skaug V; Mollerup S; Haugen A; Meltzer PS; Yokota J; Kanai Y; Harris CC
    J Thorac Oncol; 2015 Jul; 10(7):1037-48. PubMed ID: 26134223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.
    Garofalo A; Sholl L; Reardon B; Taylor-Weiner A; Amin-Mansour A; Miao D; Liu D; Oliver N; MacConaill L; Ducar M; Rojas-Rudilla V; Giannakis M; Ghazani A; Gray S; Janne P; Garber J; Joffe S; Lindeman N; Wagle N; Garraway LA; Van Allen EM
    Genome Med; 2016 Jul; 8(1):79. PubMed ID: 27460824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing.
    Doble B; John T; Thomas D; Fellowes A; Fox S; Lorgelly P
    Lung Cancer; 2017 May; 107():22-35. PubMed ID: 27316470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Present and future molecular testing of lung carcinoma.
    Dacic S; Nikiforova MN
    Adv Anat Pathol; 2014 Mar; 21(2):94-9. PubMed ID: 24508692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell death in cancer therapy of lung adenocarcinoma.
    Zagryazhskaya A; Gyuraszova K; Zhivotovsky B
    Int J Dev Biol; 2015; 59(1-3):119-29. PubMed ID: 26374533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
    Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
    Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted sequencing may facilitate differential diagnostics of pulmonary tumours: a case series.
    Ericson-Lindquist K; Johansson A; Levéen P; Elmberger G; Jönsson G; Staaf J; Brunnström H
    Diagn Pathol; 2017 Mar; 12(1):31. PubMed ID: 28347348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification.
    Oh DY; Jung K; Song JY; Kim S; Shin S; Kwon YJ; Oh E; Park WY; Song SY; Choi YL
    BMC Cancer; 2017 Aug; 17(1):535. PubMed ID: 28806950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oncogenic drivers in daily practice improve overall survival in patients with lung adenocarcinoma].
    Fournier C; Greillier L; Fina F; Secq V; Nanni-Metellus I; Loundou A; Garcia S; Ouafik L; Tomasini P; Barlesi F
    Rev Mal Respir; 2016 Nov; 33(9):751-756. PubMed ID: 27017063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers for Selection of Therapy for Adenocarcinoma of the Lung.
    Bernicker EH; Miller RA; Cagle PT
    J Oncol Pract; 2017 Apr; 13(4):221-227. PubMed ID: 28399384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
    Pécuchet N; Legras A; Laurent-Puig P; Blons H
    Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives.
    Guibert N; Ilie M; Long E; Hofman V; Bouhlel L; Brest P; Mograbi B; Marquette CH; Didier A; Mazieres J; Hofman P
    Curr Mol Med; 2015; 15(5):418-32. PubMed ID: 25941815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
    Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
    Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.